NCT01476202CompletedPhase 2
A Pilot Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Strip, Nicorette ® Nicotine Lozenge and Gum
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Mean Change From Baseline in Nicotine Craving Score on a VAS
Study Overview
Brief Summary
This study is designed to assess the ability of the mint nicotine mouth strip to relieve provoked cigarette craving in light smokers compared to nicotine lozenge and nicotine gum.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Smoking Status: Current cigarette smokers who have smoked regularly for at least a year and smoke their first cigarette more than 30 minutes after waking up.
Exclusion Criteria
- •Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to nicotine (or closely related compounds) or any of the stated ingredients in formulation.
- •Prior Concomitant Medication: a. Treatment with known enzyme altering agents (e.g. carbamazepine, phenytoin, cimetidine, sodium valporate) within 30 days of the craving provocation visit. b. Use of any prescription psychoactive medication (such as but not limited to antidepressants, antipsychotics, anxiolytics) within 14 days of the craving provocation visit. c. Use of any over-the-counter (OTC) medication that affects central nervous system such as antihistamines, sedating agents, or any compound that would have a sedating effect within 24 hours of the craving provocation visit. d. Use of any nicotine replacement therapy or any other treatment for smoking cessation (e.g. bupropion or varenicline) within one month of screening visit. e. Use of any nicotine containing products at any time during the Provocation/Treatment visit. f. Use of any medications noted in the exclusion criteria, or use of any product that would, in the opinion of the investigator, jeopardize the safety of the subject or impact on the validity of the study results.
- •Any disease that, in the opinion of the investigator, may interfere with the absorption, metabolism or excretion of the study product. A medical history that, in the opinion of the investigator, might jeopardise the safety of the subject or the validity of the study results. For example, recent myocardial infarction or cerebrovascular accident (within 12 weeks of the screening visit), phenylketonuria, unstable or worsening angina pectoris, Prinzmetals angina or severe cardiac arrhythmia.
- •Expired Carbon Monoxide (CO): Any subject whose CO level rises during the sequestration period (i.e., the subject's expired CO assessments immediately prior to the provoked craving paradigm are higher than the mean baseline CO assessment) and, in the opinion of the investigator, may have smoked during that time.
- •Alcohol: Consumption of any alcoholic beverage within 24 hours of the craving provocation visit, as indicated by a positive breath alcohol test.
Arms & Interventions
nicotine gum
Active Comparator
single dose
Intervention: nicotine (Drug)
Nicotine mouth strip
Experimental
single dose
Intervention: nicotine (Drug)
nicotine lozenge
Active Comparator
single dose
Intervention: nicotine (Drug)
Outcomes
Primary Outcomes
Mean Change From Baseline in Nicotine Craving Score on a VAS
Time Frame: Baseline, 50 seconds, 3, 5, 7, 10, 15, 20, 25 and 30 minutes post treatment administration
Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.
Secondary Outcomes
- Log Transformed Area Under the Curve of Nicotine Craving Score (AUC)(Baseline, 50 seconds, 3, 5, 7, 10, 15, 20, 25, and 30 minutes post treatment administration)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Nicotine Mouth Film for Craving Relief.Smoking CessationNCT01702532GlaxoSmithKline320
Completed
Phase 2
Evaluation of the Nicotine Lozenge in Relief of Provoked Acute CravingSmokingSmoking CessationNCT01466361GlaxoSmithKline187
Completed
Phase 2
Provoked Craving AssessmentSmoking DependenceSmokingNCT01506908GlaxoSmithKline323
Completed
Phase 4
Pilot Study: Preoperative Nicotine LozengesSmokingNCT00586482Mayo Clinic46
Completed
Not Applicable
A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth RinseDry MouthNCT04152642Procter and Gamble22